🔮 OOTWOracle · All predictions · Odds sheet · Track record · Benchmark

DEA maintains Schedule I classification through 2026 even if FDA approves MDMA.

Predicted 2026-06-23 · Resolves 2026-12-31 · regulatory · USA
78%
ORACLE CONFIDENCE
⏳ Pending
Every outcome is scored publicly in the ledger.

Even if the FDA (the US drug regulator) approves MDMA as a medicine, a separate government agency called the DEA (the Drug Enforcement Administration) controls which drugs are legal to possess. That rescheduling review takes at least a year, so MDMA will almost certainly stay in the most restricted legal category through 2026. This means patients can't just walk into a pharmacy to get it — the two approval processes don't move in sync.

FDA approval triggers a rescheduling review, not automatic descheduling. That process runs 12+ months minimum. My division does not move fast, and abuse-potential concerns remain documented.

5 new falsifiable predictions, every day at 12:05 PM ET.
Get tomorrow's Oracle →